Please login to the form below

Not currently logged in
Email:
Password:

Brexafemme

This page shows the latest Brexafemme news and features for those working in and with pharma, biotech and healthcare.

FDA approves Scynexis’ Brexafemme for recurrent vulvovaginal candidiasis

FDA approves Scynexis’ Brexafemme for recurrent vulvovaginal candidiasis

The US Food and Drug Administration (FDA) has approved a second indication for Scynexis’ Brexafemme (ibrexafungerp tablets) for the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC). ... This advantage of Brexafemme over placebo

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...